Tobiano is a white spotting pattern in horses caused by a dominant gene, Tobiano(TO). Here, we report TO associated with a large paracentric chromosome inversion on horse chromosome 3. DNA sequences flanking the inversion were identified and a PCR test was developed to detect the inversion. The inversion was only found in horses with the tobiano pattern, including horses with diverse genetic backgrounds, which indicated a common genetic origin thousands of years ago. The inversion does not interrupt any annotated genes, but begins approximately 100 kb downstream of the KIT gene. This inversion may disrupt regulatory sequences for the KIT gene and cause the white spotting pattern. This manuscript is accompanied by supplemental figures S1, S2 and S3, as well as supplemental Tables S1 and S2 ( The DNA sequence generated in this work has been submitted to GenBank under the following accession number: EF442014.

Berrozpe G, Timokhina I, Yukl S, Tajima Y, Ono M, et al: The Wsh, W57 and Ph Kit expression mutations define tissue-specific control elements located between –23 and –154 kb upstream of Kit. Blood 94:2658–2666 (1999).
Bowling AT: Equine linkage group II: phase conservation of To with AlB and GcS. J Hered 78:248–250 (1987).
Brooks S: Studies of genetic variation at the KIT locus and white spotting patterns in the horse. Ph D dissertation, University of Kentucky, Lexington KY, USA (2006).
Brooks SA, Terry RB, Bailey E: A PCR-RFLP for KIT associated with tobiano spotting pattern in horses. Anim Genet 33:301–303 (2002).
Chowdhary BP, Raudsepp T, Kata SR, Goh G, Millon LV, et al: The first-generation whole-genome radiation hybrid map in the horse identifies conserved segments in human and mouse genomes. Genome Res 13:742–751 (2003).
Duffield DA, Goldie PL: Tobiano spotting pattern in horses: linkage of To with AlA and linkage disequilibrium. J Hered 89:104–106 (1998).
Duttlinger R, Manova K, Chu TY, Gyssler C, Zelenetz AD, et al: W-sash affects positive and negative elements controlling c-kit expression: ectopic c-kit expression at sites of kit-ligand expression affects melanogenesis. Development 118:705–717 (1993).
Hough R, Lengeling A, Bedian V, Lo C, Bucan M: Rump-white inversion in the mouse disrupts dipeptidyl aminopeptidase-like protein 6 and causes dysregulation of KIT expression. Proc Natl Acad Sci USA 95:13800–13805 (1998).
Karolchik D, Baertsch R, Diekhans M, Furey TS, Hinrichs A, et al: The UCSC Genome Browser Database. Nucleic Acids Res 31:51–54 (2003).
Kent WJ: BLAT – The BLAST-Like Alignment Tool. Genome Res 12:656–664 (2002).
Kluppel M, Nagle D, Bucan M, Bernstein A: Long-range genomic rearrangements upstream of KIT dysregulate the developmental pattern of KIT expression in W57 a Wbanded mice and interfere with distinct steps in melanocyte development. Development 124:65–77 (1997).
Lear TL, Brandon R, Piumi F, Terry RR, Guerin G, et al: Mapping of 31 horse genes in BACs by FISH. Chromosome Res 9:261–262 (2001).
Leeb T, Vogl C, Zhu B, de Jong PJ, Binns MM, et al: A human-horse comparative map based on equine BAC end sequences. Genomics 87:772–776 (2006).
Locke MM, Penedo MC, Bricker SJ, Millon LV, Murray JD: Linkage of the grey coat colour locus to microsatellites on horse chromosome 25. Anim Genet 33:329–337 (2002).
Lupski JR: Genome structural variation and sporadic disease traits. Nat Genet 38:974–976 (2006).
Madan K: Paracentric inversions: a review. Hum Genet 96:503–515 (1995).
Maston GA, Evans SK, Green MR: Transcriptional regulatory elements in the human genome. Annu Rev Genomics Hum Genet 7:29–59 (2006).
Murphy BA, Lear TL, Adelson DL, Fitzgerald BP: Chromosomal assignments and sequences for the equine core circadian clock genes. Anim Genet 38:84–85 (2007).
Nagle D, Martin-DeLeon P, Hough R, Bucan M: Structural analysis of chromosomal rearrangements associated with the developmental mutations Ph, W19H, and Rw on mouse chromosome 5. Proc Natl Acad Sci USA 91:7237–7241 (1994).
Nagle DL, Kozak CA, Mano H, Chapman VM, Bucan M: Physical mapping of the Tec and Gabrb1 loci reveals that the Wsh mutation on mouse chromosome 5 is associated with an inversion. Hum Mol Genet 4:2073–2079 (1995).
Pettenati MJ, Rao PN, Phelan MC, Grass F, Rao KW, et al: Paracentric inversions in humans: a review of 446 paracentric inversions with presentation of 120 new cases. Am J Med Genet 55:171–187 (1995).
Raudsepp T, Kijas J, Godard S, Guerin G, Andersson L, Chowdhary BP: Comparison of horse chromosome 3 with donkey and human chromosomes by cross-species painting and heterologous FISH mapping. Mamm Genome 10:277–282 (1999).
Stefansson H, Helgason A, Thorleifsson G, Steinthorsdottir V, Masson G, et al: A common inversion under selection in Europeans. Nat Genet 37:129–137 (2005).
Stephenson DA, Lee KH, Nagle DL, Yen CH, Morrow A, et al: Mouse rump-white mutation associated with an inversion of chromosome 5. Mamm Genome 5:342–348 (1994).
Trommershausen-Smith A: Linkage of tobiano coat spotting and albumin markers in a pony family. J Hered 69:214–216 (1978).
Tuzun E, Sharp AJ, Bailey JA, Kaul R, Morrison VA, et al: Fine-scale structural variation of the human genome. Nat Genet 37:727–732 (2005).
Vila C, Leonard JA, Gotherstrom A, Marklund S, Sandberg K, et al: Widespread origins of domestic horse lineages. Science 291:474–477 (2001).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.